Alzheimer’s drug, the monoclonal antibody lecanemab, slowed decline in a phase 3 clinical trial, the company said.
Related Articles
-
Cancer patients often do better with less intensive treatment, research shows
Scaling back treatment for three kinds of cancer can make life easier for patients without compromising outcomes, doctors reported...
-
Landmark study of cancer in Black women launches in 20 states, aiming to be largest ever
The risk of dying from cancer has steadily declined in the U.S. over the last few decades, but Black...
-
Unsafe bedding still causes 3 out of 4 unexpected infant deaths, CDC finds
A majority of unexpected deaths among young babies still involve soft bedding, despite decades of safe-sleep messaging targeting new...
-
John Cena reveals past skin cancer diagnosis: ‘That phone call’s not one you want to get’
John Cena is opening up about a past skin cancer diagnosis in an effort to bring attention to the...
-
Measles outbreak surpasses 200 cases in Texas and New Mexico
SEMINOLE, Texas — The measles outbreak in West Texas has soared to 198 cases, the Texas Department of State...
-
Gaza hospitals face a ‘tsunami of wounded’ as supplies and power run out
GAZA CITY, Gaza — Om Hamza Mesleh, 45, was searching desperately for her son when she saw a young...
-
Who is being hospitalized for Covid-19? The unvaccinated
There are only three Covid-19 patients at Sandra Atlas Bass Heart Hospital at North Shore University Hospital, on Long...
-
Doctors call for changes to laws that criminalize drug use during pregnancy
Brandi Williams had been up for two straight days smoking crack cocaine when she realized she was going into...
Recent Comments